当前位置: X-MOL 学术Eye › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Phacoemulsification combined with micropulse cyclodiode laser in glaucoma patients: efficacy and safety
Eye ( IF 3.9 ) Pub Date : 2021-11-06 , DOI: 10.1038/s41433-021-01826-1
Arij Daas 1, 2 , Thomas Sherman 1, 2 , Lina Danieliute 1, 2 , Saurabh Goyal 1 , Andrew Amon 1 , Ian Rodrigues 1 , Ayesha Karimi 2 , Kin Sheng Lim 1, 2
Affiliation  

Objective

To evaluate the safety and efficacy of phacoemulsification combined with Micropulse transscleral cyclophotocoagulation (MP-TSCPC) in glaucoma patients.

Methods

This is a retrospective case-note review. The participants were adult patients with diagnoses of glaucoma and cataract who required a further reduction in IOP or a reduction in the number of glaucoma drops. All consecutive patients who underwent cataract surgery (CS) combined with MP-TSCPC laser between October 2018 and July 2019 were included in the study. The effect on visual acuity (VA), intraocular pressure (IOP) and number of anti-glaucoma drops were evaluated at 6 and 12 months in addition to any complications that occurred during any time point of the study.

Results

42 eyes were included in the study. Mean IOP was reduced from 19.5 ± 5.4 mmHg by 22.5% to 15.1 ± 4.6 at 6 months post-operatively and by 19.5% to 15 ± 6.6 mm Hg at 12 months (p < 0.001 at both time points). The number of anti-glaucoma medications also reduced significantly from 2.8 ± 1.3 to 1.6 ± 1.2 at 6 months and to 2.2 ± 1.3 at 12 months (p < 0.001 at both time points). The success rate was 56% at 6 months and 54% at 12 months. 54.7% of our patients who completed 12 months follow up had an improvement or unchanged vision at the last visits.

Conclusion

This is the first study evaluating the effect of cataract surgery combined with MP-TSCPC in glaucoma patients. We demonstrated that this led to a reduction in IOP and the number of anti-glaucoma medications at 6 and 12-month postoperatively. The majority of patients had either stable or better vision at 12 months follow-up.



中文翻译:

超声乳化联合微脉冲环二极管激光治疗青光眼:疗效和安全性

客观的

评价超声乳化联合微脉冲经巩膜睫状体光凝术(MP-TSCPC)治疗青光眼患者的安全性和有效性。

方法

这是一个回顾性案例注释审查。参与者是诊断为青光眼和白内障的成年患者,他们需要进一步降低眼压或减少青光眼滴剂的数量。所有在 2018 年 10 月至 2019 年 7 月期间接受白内障手术(CS)联合 MP-TSCPC 激光的连续患者均纳入研究。除了在研究的任何时间点发生的任何并发症外,在 6 个月和 12 个月评估对视力 (VA)、眼压 (IOP) 和抗青光眼滴剂次数的影响。

结果

该研究包括42只眼睛。术后 6 个月时,平均眼压从 19.5 ± 5.4 mmHg 降低 22.5% 至 15.1 ± 4.6,在 12 个月时降低 19.5% 至 15 ± 6.6 mmHg( 两个时间点p < 0.001)。抗青光眼药物的数量在 6 个月时也从 2.8 ± 1.3 显着减少至 1.6 ± 1.2,在 12 个月时降至 2.2 ± 1.3( 两个时间点的p < 0.001)。6 个月时的成功率为 56%,12 个月时为 54%。在我们完成 12 个月随访的患者中,54.7% 的患者在最后一次就诊时视力有所改善或没有变化。

结论

这是第一项评估白内障手术联合 MP-TSCPC 对青光眼患者疗效的研究。我们证明,这导致术后 6 个月和 12 个月时眼压和抗青光眼药物数量减少。大多数患者在 12 个月的随访中视力稳定或更好。

更新日期:2021-11-07
down
wechat
bug